FDA Rejects Unicycive and Sobi Filings Over Contract Manufacturing Deficiencies

FDA Rejects Unicycive's OLC Filing Due to Manufacturing Deficiencies

Unicycive Therapeutics received a second Complete Response Letter (CRL) from the FDA for its drug, oxylanthanum carbonate (OLC), intended for treating hyperphosphatemia in patients with chronic kidney disease on dialysis. The rejection was attributed to previously identified deficiencies at a third-party manufacturing vendor, which the FDA has yet to inspect as part of its review. This news significantly impacted Unicycive's share price, which fell 47% in early trading. Despite the setback, Unicycive's CEO remains optimistic about a successful inspection of the vendor and an expeditious resubmission of the New Drug Application (NDA).

• Unicycive's second Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) was issued due to persistent deficiencies at its third-party manufacturing vendor. The FDA had not yet inspected this vendor as part of its review, despite Unicycive's belief in the vendor's progress and inspection readiness, following a similar rejection a year prior.
• The announcement of the CRL led to a substantial 47% drop in Unicycive's share price, falling to $4.09 in early trading. However, Unicycive CEO Shalabh Gupta expressed optimism, stating confidence in a successful inspection of the third-party manufacturing vendor in the coming weeks and an expeditious resubmission of the NDA.
• Analysts anticipate that a successful manufacturing inspection would allow for a prompt resubmission of the OLC NDA. This resubmission is expected to receive a two-month review, suggesting that the product could still potentially be approved later in the current year, offering a potential recovery path for Unicycive.

Oxylanthanum Carbonate's Safety Profile Amidst Regulatory Setbacks

Across phase 1 and phase 2 clinical studies, oxylanthanum carbonate (OLC) has demonstrated a consistently favorable tolerability profile. In a double-blind, dose-escalation phase 1 study enrolling 32 healthy volunteers, OLC was well tolerated across all evaluated dose levels (500, 1000, 1500, and 2000 mg three times daily). A subsequent phase 1 crossover study in 80 randomized subjects (75 receiving all doses) confirmed that OLC 1000 mg three times daily was well tolerated with an incidence of adverse events comparable to lanthanum carbonate, and the two agents were shown to be bioequivalent in healthy subjects. Systemic lanthanum absorption remained minimal throughout these studies: serum lanthanum concentrations were below the level of quantification (0.500 ng/mL) in all subjects receiving 500 mg three times daily and did not exceed 0.7 ng/mL at higher doses, reinforcing the low systemic exposure anticipated with this mechanism of action.

In a phase 2 open-label trial involving 86 patients receiving maintenance hemodialysis, OLC was well tolerated at clinically effective doses. The most common treatment-related adverse events (TRAEs) were gastrointestinal in nature — diarrhea (9%) and vomiting (6%) — consistent with the class-wide profile of phosphate binders. All remaining TRAEs were reported in fewer than 5% of patients, and only 3 patients (4%) discontinued treatment due to TRAEs. Minimal to no systemic lanthanum absorption was again observed at the 1000 mg thrice-daily dose in this renally impaired population. Notably, effective serum phosphate control was achieved in over 90% of patients, with two-thirds requiring three or fewer tablets per day — a pill burden advantage that distinguishes OLC from many existing phosphate binders.

Contextualizing OLC's profile against the broader lanthanum carbonate (LC) literature provides additional reassurance. Long-term LC data spanning up to six years in patients with end-stage renal disease showed treatment-related adverse events in 25.8% of patients, predominantly gastrointestinal, with no clinically relevant changes in liver function and no evidence of adverse effects on bone or the central nervous system. OLC's safety signals to date are consistent with this established class profile. As with other phosphate-lowering agents, gastrointestinal side effects remain the primary tolerability consideration, but the low daily dose volume of OLC — the smallest among commercially available phosphate binders per gram of phosphate bound — may offer a practical advantage in supporting patient adherence.

Evolving Treatment Landscape for Hyperphosphatemia in CKD

Over the past five years, the treatment landscape for hyperphosphatemia in CKD patients on dialysis has undergone meaningful expansion, driven by both refined evidence on established phosphate binders and the emergence of mechanistically distinct agents. Large-scale network meta-analyses have clarified the comparative performance of traditional binders: a 2023 analysis of 94 trials comprising 14,459 participants identified magnesium carbonate as having the greatest phosphorus-lowering effect (mean difference: −1.61 mg/dL vs. placebo), while ferric citrate demonstrated the most favorable efficacy-to-acceptability profile, showing significantly fewer treatment discontinuations (OR 0.56; 95% CrI: 0.36–0.89). A separate meta-analysis of 127 RCTs with 20,215 patients confirmed that both sevelamer (RR 0.610; 95% CI: 0.401–0.929) and lanthanum carbonate (RR 0.467; 95% CI: 0.337–0.647) significantly reduced all-cause mortality, though neither demonstrated a statistically significant effect on cardiovascular mortality or events. Real-world evidence for sucroferric oxyhydroxide (SO) has also accumulated, with peritoneal dialysis data showing that SO monotherapy increased the proportion of patients achieving serum phosphorus ≤5.5 mg/dL from 32.1% at baseline to 46.5–54.0% over one year, while simultaneously reducing mean daily pill burden from 7.7 to 4.6–5.4 tablets — an important consideration for treatment adherence.

The most clinically significant development in this period has been the introduction of tenapanor, a first-in-class, minimally systemic sodium-hydrogen exchanger 3 (NHE3) inhibitor with a mechanism entirely distinct from conventional phosphate binders. By modulating intestinal tight junctions and downregulating NaPi2b transporter expression, tenapanor reduces both paracellular and transcellular phosphate absorption. Meta-analytic data from eight clinical trials (n = 1,001) confirmed a mean serum phosphate reduction of −1.39 mg/dL versus placebo (95% CI: −1.94 to −0.84; p < 0.0001), with 2.80-fold greater likelihood of achieving target serum phosphate ≤5.5 mg/dL (95% CI: 1.70–4.61; p < 0.0001). Long-term data from the NORMALIZE study (18-month follow-up) demonstrated that 35–49% of patients achieved serum phosphate ≤4.5 mg/dL using tenapanor alone or in combination with phosphate binders, alongside significant reductions in FGF23 and, in patients with iPTH ≥300 pg/mL, intact parathyroid hormone. The most common adverse event was diarrhea (22%), leading to discontinuation in only 2% of patients. Secondary to pharmacological advances, high-volume hemodiafiltration has also garnered attention as a dialysis modality enhancement: kinetic modeling predicts approximately 15–20% higher dialytic phosphate clearance compared to standard hemodialysis, corresponding to an estimated 0.5 mg/dL reduction in predialysis serum phosphate when nondialytic factors are held constant.

Emerging pipeline agents and mechanistic approaches further signal continued evolution of the field. Early-stage data support the promise of selective Npt2a inhibitors — including PF-06869206 and BAY-767 — which exert phosphaturic effects by targeting renal tubular phosphate reabsorption, with BAY-767 additionally attenuating vascular calcification in preclinical models. Novel agents such as AP306/EOS789, an inhibitor of active transcellular phosphate transporters, and oxylanthanum carbonate, a reformulated lanthanum-based binder with a reduced pill size, are also under investigation. Critically, a large registry-based analysis of 31,989 incident dialysis patients from Australia and New Zealand (2008–2018) reinforced the clinical urgency of phosphate control, demonstrating a U-shaped association between serum phosphate and all-cause mortality — with serum phosphate ≥2.75 mmol/L carrying an adjusted hazard ratio of 2.13 (95% CI: 1.93–2.36) compared to the reference range of 1.25–1.99 mmol/L. Collectively, these developments underscore a shift toward individualized, mechanism-informed phosphate management strategies that extend beyond conventional binder therapy.

Manufacturing Hurdles Stall a Promising Hyperphosphatemia Therapy

The landscape of hyperphosphatemia management in chronic kidney disease (CKD) patients on dialysis is complex, marked by a persistent need for more effective and tolerable therapies. Elevated serum phosphate levels are strongly associated with increased cardiovascular morbidity and mortality, yet achieving optimal control remains a challenge. Current treatment paradigms, primarily involving dietary restrictions and phosphate binders, often struggle with patient adherence due to high pill burdens and gastrointestinal side effects.

Oxylanthanum carbonate (OLC) emerged as a promising non-calcium-based phosphate binder, with Phase 2 data indicating its ability to control serum phosphate in over 90% of patients with a notably low pill burden. This characteristic is particularly significant, as improving adherence to phosphate binder therapy has been shown to lead to increased cost savings in total Medicare and inpatient costs. The potential for OLC to offer a more patient-friendly option could have meaningfully impacted clinical practice and patient outcomes.

However, the recent second Complete Response Letter from the FDA, citing unresolved manufacturing deficiencies at a third-party vendor, casts a shadow over OLC's immediate future. This regulatory setback underscores that even a drug with a favorable clinical profile can be derailed by non-clinical issues related to manufacturing quality and supply chain integrity. For Unicycive, this means a significant delay in market entry, impacting revenue projections and potentially allowing competitors to further solidify their positions. The broader market, which includes established non-calcium binders like sevelamer and ferric citrate, will continue to evolve, with ongoing research exploring novel phosphate transport inhibitors and the role of biomarkers beyond serum phosphorus. While the need for therapies that improve hard clinical outcomes beyond biochemical markers remains a critical area for future research, the immediate focus for OLC will be on resolving these manufacturing hurdles to bring a potentially valuable treatment option to patients who desperately need it.